Caption Management’s Arbutus Biopharma ABUS Stock Holding History

Caption Management’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-100,000	Closed	-$481K	–	1493
2025 Q4	$481K	Buy	+100,000	New	+$450K	﹤0.01%	1253
2025 Q2	–	Sell	-75,000	Closed	-$262K	–	1390
2025 Q1	$262K	Sell	75,000 -100,000	-57%	-$333K	﹤0.01%	1225
2024 Q4	$572K	Buy	+175,000	New	+$644K	0.01%	1070
2024 Q1	–	Sell	-200,000	Closed	-$500K	–	1136
2023 Q4	$500K	Hold	200,000	–	–	0.01%	967
2023 Q3	$406K	Buy	200,000 +100,000	+100%	+$210K	0.01%	981
2023 Q2	$230K	Hold	100,000	–	–	﹤0.01%	915
2023 Q1	$303K	Hold	100,000	–	–	0.01%	878
2022 Q4	$233K	Hold	100,000	–	–	﹤0.01%	1045
2022 Q3	$192K	Sell	100,000 -100,000	-50%	-$235K	﹤0.01%	1246
2022 Q2	$542K	Sell	200,000 -200,000	-50%	-$512K	0.01%	1058
2022 Q1	$1.19M	Buy	400,000 +225,000	+129%	+$689K	0.01%	913
2021 Q4	$682K	Buy	175,000 +120,000	+218%	+$466K	0.01%	1169
2021 Q3	$236K	Sell	55,000 -45,000	-45%	-$150K	﹤0.01%	1321
2021 Q2	$303K	Buy	+100,000	New	+$310K	﹤0.01%	1130
2019 Q1	–	Sell	-30,000	Closed	-$115K	–	543
2018 Q4	$115K	Buy	+30,000	New	+$148K	0.01%	419

Other funds holding ABUS

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

WCM

Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Caption Management's ABUS Position: Q3 2025 in Review

Caption Management sold out of Arbutus Biopharma (ABUS) in Q3 2025, closing a stake of 41,866 shares — an estimated $129K sold.

Caption Management first reported a position in ABUS in Q4 2018 and held it in 13 quarters. The position peaked at $228K in Q4 2024. 166 funds tracked by Wall St. Rank hold ABUS as of Q3 2025.

Caption Management reported no remaining Arbutus Biopharma position as of Q3 2025 after selling out during the quarter.
Caption Management sold 41,866 Arbutus Biopharma shares in Q3 2025, an estimated $129K.
Caption Management first reported a position in Arbutus Biopharma in Q4 2018 and held it in 13 quarters.
Caption Management's Arbutus Biopharma position peaked at $228K in Q4 2024.
166 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2025.

Based on Caption Management's 13F filing for Q3 2025, filed 14 Nov 2025.